Poised to receive the Food and Drug Administration's green light on its drug-eluting stent, Boston Scientific Corp., Natick, Mass., reported a 15% jump in revenue for the fourth quarter ended Dec. 31, 2003, and a 19% jump for the year. Internationally, the company's drug-eluting stent -- the hottest ticket in cardiac care of late -- outsold Johnson & Johnson's Cypher, which has been enjoying exclusivity in the U.S. market since it was approved by the FDA last spring, according to David Lothson, an analyst for UBS. Lothson predicted in a report released Monday that FDA approval of Boston Scientific's Taxus stent "is likely within the next few weeks." For the fourth quarter, the company earned $141 million, or 17 cents per share, on net sales of $939 million. That compares with earnings of $130 million, or 15 cents per share, on revenue of $814 million in the year-ago period. For the year, Boston Scientific earned $521 million, or 62 cents per share, on net sales of $3.5 billion, up from net income of $413 million, or 50 cents per share, on revenue of $2.9 billion in 2002. -- by Cinda Becker
Boston Scientific sales rise; new stent near market
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.